Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin.

Literature DB >> 101128

beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin.

Abstract

The stability to beta-lactamase hydrolysis of HR 756, a new cephalosporin antibiotic, was compared to the beta-lactamase stability of cefoxitin and cefuroxime. HR 756, cefoxitin, and cefuroxime were not hydrolyzed by Richmond type I, III, IV, and V beta-lactamases. Antibacterial activity of HR 756 correlated well with resistance to beta-lactamase hydrolysis except against Pseudomonas aeruginosa. HR 756, cefoxitin, and cefuroxime inhibited type I beta-lactamases, but not type III, IV, or V enzymes. HR 756 was the most active inhibitor.

Entities: Chemical Species

Mesh：

Substances：

Year: 1978 PMID： 101128 PMCID： PMC352458 DOI： 10.1128/AAC.14.3.322

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

13 in total

1. Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus.

Authors: C Reading; M Cole
Journal: Antimicrob Agents Chemother Date: 1977-05 Impact factor: 5.191

2. Formation of beta-lactamase in Bacteroides fragilis: cell-bound and extracellular activity.

Authors: B Olsson; C E Nord; T Wadström
Journal: Antimicrob Agents Chemother Date: 1976-05 Impact factor: 5.191

Review 3. The beta-lactamases of gram-negative bacteria and their possible physiological role.

Authors: M H Richmond; R B Sykes
Journal: Adv Microb Physiol Date: 1973 Impact factor: 3.517

4. Experimental evaluation of HR756, a new cephalosporin derivative: pre-clinical study.

Authors: R Heymès; A Lutz; E Schrinner
Journal: Infection Date: 1977 Impact factor: 3.553

5. Inhibition of beta-lactamases by beta-lactam antibiotics.

Authors: C O'Callaghan; A Morris
Journal: Antimicrob Agents Chemother Date: 1972-12 Impact factor: 5.191

6. Potent combinations of beta-lactam antibiotics using the beta-lactamase inhibition principle.

Authors: D Greenwood; F O'Grady
Journal: Chemotherapy Date: 1975 Impact factor: 2.544

7. Cefoxitin, a semisynthetic cephamycin antibiotic: antibacterial spectrum and resistance to hydrolysis by gram-negative beta-lactamases.

Authors: H C Neu
Journal: Antimicrob Agents Chemother Date: 1974-08 Impact factor: 5.191

8. In vitro synergistic effect of netilmicin, a new aminoglycoside antibiotic.

Authors: K P Fu; H C Neu
Journal: Antimicrob Agents Chemother Date: 1976-09 Impact factor: 5.191

9. Inhibition of the -lactamases of Escherichia coli and Klebsiella aerogenes by semi-synthetic penicillins.

Authors: M Cole; S Elson; P D Fullbrook
Journal: Biochem J Date: 1972-03 Impact factor: 3.857

10. Cefoxitin resistance to beta-lactamase: a major factor for susceptibility of bacteroides fragilis to the antibiotic.

Authors: G Darland; J Birnbaum
Journal: Antimicrob Agents Chemother Date: 1977-04 Impact factor: 5.191

59 in total

1. Activity of beta-lactam antibiotics against Pseudomonas aeruginosa carrying R plasmids determining different beta-lactamases.

Authors: G A Jacoby; L Sutton
Journal: Antimicrob Agents Chemother Date: 1979-08 Impact factor: 5.191

9. Comparative antibacterial activities of 7 alpha-methoxy cephalosporins and 7 beta-methoxyiminoacetamido cephalosporins against Bacteroides fragilis.

Authors: T Kesado; K Watanabe; Y Asahi; M Isono; K Ueno
Journal: Antimicrob Agents Chemother Date: 1984-01 Impact factor: 5.191

Review 10. In vitro activity of cefodizime.

Authors: H Knothe; P M Shah
Journal: Infection Date: 1992 Impact factor: 3.553

beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin.

1. Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus.

2. Formation of beta-lactamase in Bacteroides fragilis: cell-bound and extracellular activity.

Review 3. The beta-lactamases of gram-negative bacteria and their possible physiological role.

4. Experimental evaluation of HR756, a new cephalosporin derivative: pre-clinical study.

5. Inhibition of beta-lactamases by beta-lactam antibiotics.

6. Potent combinations of beta-lactam antibiotics using the beta-lactamase inhibition principle.

7. Cefoxitin, a semisynthetic cephamycin antibiotic: antibacterial spectrum and resistance to hydrolysis by gram-negative beta-lactamases.

8. In vitro synergistic effect of netilmicin, a new aminoglycoside antibiotic.

9. Inhibition of the -lactamases of Escherichia coli and Klebsiella aerogenes by semi-synthetic penicillins.

10. Cefoxitin resistance to beta-lactamase: a major factor for susceptibility of bacteroides fragilis to the antibiotic.

1. Activity of beta-lactam antibiotics against Pseudomonas aeruginosa carrying R plasmids determining different beta-lactamases.

2. In vitro activity of HR 756, a new cephalosporin, against Neisseria gonorrhoeae.

3. Antibiotic Resistance of LACTOBACILLUS Strains.

4. The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction.

5. Bone and joint infections caused by gram-positive bacteria: treatment with cefotaxime.

6. Penem derivatives: beta-lactamase stability and affinity for penicillin-binding proteins in Escherichia coli.

7. What do beta-lactamases mean for clinical efficacy?

8. Human pharmacology of cefotaxime (HR 756), a new cephalosporin.

9. Comparative antibacterial activities of 7 alpha-methoxy cephalosporins and 7 beta-methoxyiminoacetamido cephalosporins against Bacteroides fragilis.

Review 10. In vitro activity of cefodizime.